Trial Profile
Tisagenlecleucel Versus Blinatumomab or Inotuzumab for Adult Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia: A Randomized Open Label, Multicenter, Phase III Trial
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 15 Jun 2022
Price :
$35
*
At a glance
- Drugs Tisagenlecleucel (Primary) ; Blinatumomab; Inotuzumab ozogamicin
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms OBERON
- Sponsors Novartis Pharmaceuticals
- 07 Jul 2020 Planned End Date changed from 8 Oct 2025 to 7 Jan 2026.
- 07 Jul 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 26 May 2020 Planned initiation date changed from 2 Apr 2020 to 5 Jun 2020.